Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
63.12
+0.44 (0.70%)
At close: May 22, 2026, 4:00 PM EDT
61.86
-1.26 (-2.00%)
After-hours: May 22, 2026, 4:43 PM EDT
Monopar Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Monopar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $112.62. The average 1-year stock price forecast is 78.42% higher than the current stock price, while the lowest is $100 (+58.43%) and the highest is $130 (+105.96%).
Price Target: $112.62 (+78.42%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 30, 2026.
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +58.43% | Mar 30, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +64.77% | Feb 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +64.77% | Feb 2, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +58.43% | Jan 29, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +64.77% | Jan 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
19.92M
EPS This Year
-3.01
from -1.85
EPS Next Year
-3.66
from -3.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 41.0M | ||||||
| Avg | n/a | 19.9M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.43 | -1.18 | ||||||
| Avg | -3.01 | -3.66 | ||||||
| Low | -5.56 | -8.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.